

# CITATION REPORT

List of articles citing

Health utility of patients with advanced gastrointestinal stromal tumors (GIST) after failure of imatinib and sunitinib: findings from GRID, a randomized, double-blind, placebo-controlled phase III study of regorafenib versus placebo

DOI: 10.1007/s10120-014-0391-x  
Gastric Cancer, 2015, 18, 627-34.

**Source:** <https://exaly.com/paper-pdf/61198767/citation-report.pdf>

**Version:** 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
14	Regorafenib treatment for advanced, refractory gastrointestinal stromal tumor: a report of the UK managed access program. <i>Clinical Sarcoma Research</i> , <b>2014</b> , 4, 17	2.5	11
13	Targeting gastrointestinal stromal tumors: the role of regorafenib. <i>OncoTargets and Therapy</i> , <b>2016</b> , 9, 3009-16	4.4	4
12	Cost Effectiveness of Universal Hepatitis B Virus Screening in Patients Beginning Chemotherapy for Sarcomas or GI Stromal Tumors. <i>Journal of Global Oncology</i> , <b>2016</b> , 2, 186-199	2.6	3
11	The safety of regorafenib for the treatment of gastrointestinal stromal tumors. <i>Expert Opinion on Drug Safety</i> , <b>2016</b> , 15, 105-16	4.1	14
10	Cost-Effectiveness Analysis of Regorafenib for Gastrointestinal Stromal Tumour (GIST) in Germany. <i>Clinical Drug Investigation</i> , <b>2017</b> , 37, 525-533	3.2	2
9	Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , <b>2017</b> , 18, 1411-1422	21.7	49
8	Cost-Effectiveness Analysis of Tyrosine Kinase Inhibitors for Patients with Advanced Gastrointestinal Stromal Tumors. <i>Clinical Drug Investigation</i> , <b>2017</b> , 37, 85-94	3.2	2
7	Optimizing the dose in patients treated with imatinib as first line treatment for gastrointestinal stromal tumours: A cost-effectiveness study. <i>British Journal of Clinical Pharmacology</i> , <b>2019</b> , 85, 1994-2001	3.8	14
6	Cost-Effectiveness Analysis of Screening for Hepatitis B Virus Infection in Patients With Solid Tumors Before Initiating Chemotherapy. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 1600-1608.e4	6.9	4
5	Treatment of Metastatic Gastrointestinal Stromal Tumors (GIST): A Focus on Older Patients. <i>Drugs and Aging</i> , <b>2021</b> , 38, 375-396	4.7	1
4	Efficacy and Safety of Regorafenib in Korean Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib: A Multicenter Study Based on the Management Access Program. <i>Cancer Research and Treatment</i> , <b>2017</b> , 49, 350-357	5.2	14
3	Therapeutic targets in gastrointestinal stromal tumors. <i>World Journal of Translational Medicine</i> , <b>2015</b> , 4, 25	8	1
2	Health-Related Quality of Life and Side Effects in Gastrointestinal Stromal Tumor (GIST) Patients Treated with Tyrosine Kinase Inhibitors: A Systematic Review of the Literature.. <i>Cancers</i> , <b>2022</b> , 14,	6.6	0
1	Patient-reported outcomes in individuals with advanced gastrointestinal stromal tumor treated with ripretinib in the fourth-line setting: analysis from the phase 3 INVICTUS trial. <b>2022</b> , 22,		0